Indexed on: 29 Jun '17Published on: 29 Jun '17Published in: ACS Applied Materials & Interfaces
A bimodal contrast nanoagent was develop by chelating gadolinium ion to the DTDTPA modified CuInS2/ZnS quantum dots (QDs). The longitudinal relaxivity r1 of the resulted QDs@DTDTPA-Gd NPs was calculated to be 9.91 mM(-1)s(-1), which was 2.5 times as high as that of clinically-approved (3.9 mM(-1)s(-1)). In addition, the in vivo imaging experiments showed that QDs@DTDTPA-Gd NPs could enhance both near infrared fluorescence and T1-weighted magnetic resonance imaging of tumor tissue through passive targeting accumulation. Moreover, the high colloidal and fluorescence stability, and good biocompatibility indicate that QDs@DTDTPA-Gd NPs have great potential for the use as an efficient nanoagent to integrate the extremely sensitivity of the fluorescence imaging to magnetic resonance imaging with high resolution. Combination of bimodal detectability in the same agent of QDs@DTDTPA-Gd NPs can avoid extra stress on the blood clearance mechanisms as the administration of multiple dose of agents.